Compass Pathways Plc (CMPS)
Compass Pathways plc is a biotechnology company focused on mental health research in the United Kingdom and the United States. Through its listed ADR on NASDAQ, the company is developing COMP360, a psilocybin therapy candidate being studied in Phase III clinical trials for treatment-resistant depression and in Phase II trials for post-traumatic stress disorder and anorexia nervosa. The business was formerly known as COMPASS Rx Limited and adopted the Compass Pathways plc name in August 2020. Incorporated in 2020, the company is headquartered in London, United Kingdom.
Stock Summary
Fair Value
Profitability & Growth
Quality & Risk
Events & Dividends
Technical Outlook
FAQ
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CMPS
|
$11.40
|
-5.1% Downside
|
Fair
|
$24.47
|
103.7% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
July 30, 2026
|
-8.4x
|
4.9x
|
—
|
1.575 B
|
1.199 B
|
3.3%
|
75.2%
|
2.6
|
—
|
82.9%
|
